MedPath

Effect of Self-administered Smoke or Smokeless Moxibustion on Breech Presentation Converting to Cephalic Presentatio

Phase 1
Conditions
Pregnant women with a singleton breech presentation between 33 and 35 weeks of gestation
Registration Number
JPRN-UMIN000021377
Lead Sponsor
St. Luke's International University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1.Pregnancy with multiples beyond twins, risk of preterm birth (preterm uterine contractions and/or initial dilatation or shortening of the cervix with a score of 4 on the Bishop scale, tocolytic therapy), uterine fibroids > 4cm, maternal heart or kidney disease, placenta previa, complications with pregnancy-induced hypertension, pre-labor rupture of the membranes, contraindication to vaginal delivery, intrauterine growth restriction, fetal malformation or chromosomal disorder, pregnant woman or siblings of the fetus diagnosed with bronchial asthma or a pulmonary problem, and is treated (only in the intervention group) 2.previous uterine surgery, uterine malformations, bone pelvic defects, allergies of Artemisia vulgaris (only in the intervention group), pregnant woman or siblings of the fetus who have symptoms of coughing, respiratory discomfort by smoke (only in the intervention group) 3.prior treatment with moxibustion to achieve version of the fetus

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cephalic presentations at two weeks after the start of interventions.
Secondary Outcome Measures
NameTimeMethod
(1) Cephalic presentations at birth (excluding external cephalic version) (2) Birthing outcomes (the mode of birth, premature birth requiring hospitalization, preterm birth, pre-labor rupture of membranes at < 37 weeks, gestational age at birth, Apgar score < 7 at 5 min., birthweight, admission to NICU, cord blood pH less than 7.1, perinatal morbidity and mortality, (3) The number of self-reported fetal movements. (4) Side effects from using moxa sticks
© Copyright 2025. All Rights Reserved by MedPath